Postinfection therapy of arbovirus infections in mice

I. P. Singh, D. H. Coppenhaver, M. Sarzotti, P. Sriyuktasuth, J. Poast, H. B. Levy, S. Baron

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Most antiviral agents are efficacious prophylactically in vivo, and a few are efficacious for postinfection (p.i.) therapy. To explore possibilities for p.i. therapy of encephalogenic Banzi virus (BZV) and Semliki Forest virus infections in mice, we evaluated candidate antiviral therapies after development of the first clinical signs of infection. The earliest clinical indication of BZV viremia in mice is a rise in core body temperature beginning on day 3 p.i. BZV-infected mice showing elevated core body temperatures (≥37.3°C) on days 3 and 4 p.i. were treated intraperitoneally with the interferon inducer poly(ICLC) (80 μg per mouse) and/or specific antiserum. Combined therapy on day 3 of a BZV infection protected over 75% of mice showing clinical evidence of viral disease before treatment. Protection against early brain infection must occur on day 4 p.i., since by that day BZV has started multiplying in the brains of the mice. Significant protection occurred with antiserum alone and increased with poly(ICLC). Similar protection was obtained during Semliki Forest virus viremia, but this infection is so rapid that the first clinical signs are reliably detectable only after viremia.

Original languageEnglish (US)
Pages (from-to)2126-2131
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume33
Issue number12
StatePublished - 1989

Fingerprint

Arbovirus Infections
Virus Diseases
Viremia
Semliki forest virus
Viruses
Body Temperature
Antiviral Agents
Immune Sera
Therapeutics
Interferon Inducers
Brain
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Singh, I. P., Coppenhaver, D. H., Sarzotti, M., Sriyuktasuth, P., Poast, J., Levy, H. B., & Baron, S. (1989). Postinfection therapy of arbovirus infections in mice. Antimicrobial Agents and Chemotherapy, 33(12), 2126-2131.

Postinfection therapy of arbovirus infections in mice. / Singh, I. P.; Coppenhaver, D. H.; Sarzotti, M.; Sriyuktasuth, P.; Poast, J.; Levy, H. B.; Baron, S.

In: Antimicrobial Agents and Chemotherapy, Vol. 33, No. 12, 1989, p. 2126-2131.

Research output: Contribution to journalArticle

Singh, IP, Coppenhaver, DH, Sarzotti, M, Sriyuktasuth, P, Poast, J, Levy, HB & Baron, S 1989, 'Postinfection therapy of arbovirus infections in mice', Antimicrobial Agents and Chemotherapy, vol. 33, no. 12, pp. 2126-2131.
Singh IP, Coppenhaver DH, Sarzotti M, Sriyuktasuth P, Poast J, Levy HB et al. Postinfection therapy of arbovirus infections in mice. Antimicrobial Agents and Chemotherapy. 1989;33(12):2126-2131.
Singh, I. P. ; Coppenhaver, D. H. ; Sarzotti, M. ; Sriyuktasuth, P. ; Poast, J. ; Levy, H. B. ; Baron, S. / Postinfection therapy of arbovirus infections in mice. In: Antimicrobial Agents and Chemotherapy. 1989 ; Vol. 33, No. 12. pp. 2126-2131.
@article{aff3f92224f2434bbd2a2dd16d093a34,
title = "Postinfection therapy of arbovirus infections in mice",
abstract = "Most antiviral agents are efficacious prophylactically in vivo, and a few are efficacious for postinfection (p.i.) therapy. To explore possibilities for p.i. therapy of encephalogenic Banzi virus (BZV) and Semliki Forest virus infections in mice, we evaluated candidate antiviral therapies after development of the first clinical signs of infection. The earliest clinical indication of BZV viremia in mice is a rise in core body temperature beginning on day 3 p.i. BZV-infected mice showing elevated core body temperatures (≥37.3°C) on days 3 and 4 p.i. were treated intraperitoneally with the interferon inducer poly(ICLC) (80 μg per mouse) and/or specific antiserum. Combined therapy on day 3 of a BZV infection protected over 75{\%} of mice showing clinical evidence of viral disease before treatment. Protection against early brain infection must occur on day 4 p.i., since by that day BZV has started multiplying in the brains of the mice. Significant protection occurred with antiserum alone and increased with poly(ICLC). Similar protection was obtained during Semliki Forest virus viremia, but this infection is so rapid that the first clinical signs are reliably detectable only after viremia.",
author = "Singh, {I. P.} and Coppenhaver, {D. H.} and M. Sarzotti and P. Sriyuktasuth and J. Poast and Levy, {H. B.} and S. Baron",
year = "1989",
language = "English (US)",
volume = "33",
pages = "2126--2131",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Postinfection therapy of arbovirus infections in mice

AU - Singh, I. P.

AU - Coppenhaver, D. H.

AU - Sarzotti, M.

AU - Sriyuktasuth, P.

AU - Poast, J.

AU - Levy, H. B.

AU - Baron, S.

PY - 1989

Y1 - 1989

N2 - Most antiviral agents are efficacious prophylactically in vivo, and a few are efficacious for postinfection (p.i.) therapy. To explore possibilities for p.i. therapy of encephalogenic Banzi virus (BZV) and Semliki Forest virus infections in mice, we evaluated candidate antiviral therapies after development of the first clinical signs of infection. The earliest clinical indication of BZV viremia in mice is a rise in core body temperature beginning on day 3 p.i. BZV-infected mice showing elevated core body temperatures (≥37.3°C) on days 3 and 4 p.i. were treated intraperitoneally with the interferon inducer poly(ICLC) (80 μg per mouse) and/or specific antiserum. Combined therapy on day 3 of a BZV infection protected over 75% of mice showing clinical evidence of viral disease before treatment. Protection against early brain infection must occur on day 4 p.i., since by that day BZV has started multiplying in the brains of the mice. Significant protection occurred with antiserum alone and increased with poly(ICLC). Similar protection was obtained during Semliki Forest virus viremia, but this infection is so rapid that the first clinical signs are reliably detectable only after viremia.

AB - Most antiviral agents are efficacious prophylactically in vivo, and a few are efficacious for postinfection (p.i.) therapy. To explore possibilities for p.i. therapy of encephalogenic Banzi virus (BZV) and Semliki Forest virus infections in mice, we evaluated candidate antiviral therapies after development of the first clinical signs of infection. The earliest clinical indication of BZV viremia in mice is a rise in core body temperature beginning on day 3 p.i. BZV-infected mice showing elevated core body temperatures (≥37.3°C) on days 3 and 4 p.i. were treated intraperitoneally with the interferon inducer poly(ICLC) (80 μg per mouse) and/or specific antiserum. Combined therapy on day 3 of a BZV infection protected over 75% of mice showing clinical evidence of viral disease before treatment. Protection against early brain infection must occur on day 4 p.i., since by that day BZV has started multiplying in the brains of the mice. Significant protection occurred with antiserum alone and increased with poly(ICLC). Similar protection was obtained during Semliki Forest virus viremia, but this infection is so rapid that the first clinical signs are reliably detectable only after viremia.

UR - http://www.scopus.com/inward/record.url?scp=0024393340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024393340&partnerID=8YFLogxK

M3 - Article

C2 - 2619276

AN - SCOPUS:0024393340

VL - 33

SP - 2126

EP - 2131

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 12

ER -